Joined: 12/6/2011
Posts: 3326
|
From Alzheimer's Daily News:
(Source: Medscape Neurology) - Dr. Jeffrey Cummings of the the Camille and Larry Ruvo Chair for Brain Health at the Neurological Institute of Cleveland Clinic, and the Director of the Lou Ruvo Center for Brain Health in Las Vegas, Nevada, reports on three important findings in the path to treating Alzheimer's disease presented at the American Academy of Neurology 2012 Annual Meeting.
In one study, investigators reported on the sensitivity and specificity of florbetaben, one of the amyloid imaging compounds for autopsy confirmation of the presence of amyloid plaques in the brain.
In a second study Canadian researchers looked at the autopsy confirmation of the diagnosis of patients who had participated in AD clinical trials. They found evidence that suggests that we are still enrolling patients with mixed pathology in our clinical trials.
Finally, Cummings addressed the effects of memantine on behavior in patients with AD. He and his colleagues found that using the 28-mg extended-release preparation of the drug had an improvement in behavior which continued to improve over time.
Go to full story: http://www.medscape.com
|